Halozyme Provides Update on German Preliminary Injunction Hearing
FROM THE WIRE · FINANCE.YAHOO.COM
SAN DIEGO, Nov. 19, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to refrain from distributing and offering…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe overturned injunction in Germany eases legal pressure on Merck's Keytruda SC launch, a risk for Halozyme.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Higher Regional Court overturned the preliminary injunction in Germany.
- 02Halozyme will file an infringement lawsuit against Merck in Germany.
- 03A Dutch patent court separately prohibited Merck from infringing in several European countries.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Halozyme Therapeutics, Inc.92.55 USD-3.39%today -3.39%Negative Merck & Co., Inc.135.13 USD-0.17%today -1.92%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets